Skip to content

Dr. Moons Anke

Active
Private limited companyfounded 2018active for 8 yearsKruisvijverstraat 14, 3550 Heusden-Zolder, BelgiumKBO/BCE: BE 0701.835.283
Summary

Dr. Moons Anke has been active since 2018 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €18,600 and a net result of €183,501. Equity has been shrinking by about 17% per year since 2019. If that trend continues, it turns negative around financial year 2027. The computed 12-month bankruptcy probability is 0.1% (very low).

Overview

Overview

Official details

Source: KBO
Status
Active since 28-08-2018 Normal situation
Activity
“De uitoefening van de geneeskunde door de arts-aandeelhouders,zijnde meer in het bijzonder huisarts,in naam…” (deed in Dutch)From the articles, 14 activitiesNo NACE code in the KBO yet
Establishment unit
2.279.241.860 3582 Beringen, since 28-08-2018
Financial year end
31 December
Peppol
Reachable

Board and ownership

Board

Financial position

93 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.1%
Annual accounts 2025
Gross margin
€248,738
▲ 46.0%
Turnover
≈ €620,000
estimated
Profit
€183,501
▲ 46.2%
Equity
€18,600
=
Total assets
€375,083
▼ 3.4%
Score breakdownraises riskEquity €18,600 (5.0% of total assets)lowers riskSize: total assets €375,083No main activity registeredLiquidity: current ratio 1.01, cash €317,164Show the evidence

Checked score

Score 2025
93 / 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 48% of micro companies without a NACE code
Financial strength · tick: 2024
Strong
Solvency 30=
equity 5.0% of total assets
Liquidity 50=
short-term debt 94.9% · cash 84.6%
Profitability 100=
return on assets 48.9%
Bankruptcy probability within 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%

About 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Last 24 months 12-2024: 0.2% 01-2025: 0.2%● unchanged vs 12-2024 02-2025: 0.2%● unchanged vs 01-2025 03-2025: 0.2%● unchanged vs 02-2025 04-2025: 0.2%● unchanged vs 03-2025 05-2025: 0.2%● unchanged vs 04-2025 06-2025: 0.2%● unchanged vs 05-2025 07-2025: 0.2%● unchanged vs 06-2025highest value 08-2025: 0.2%● unchanged vs 07-2025 09-2025: 0.2%● unchanged vs 08-2025 10-2025: 0.2%● unchanged vs 09-2025 11-2025: 0.2%● unchanged vs 10-2025 12-2025: 0.2%● unchanged vs 11-2025 01-2026: 0.2%● unchanged vs 12-2025 02-2026: 0.2%● unchanged vs 01-2026 03-2026: 0.2%● unchanged vs 02-2026 04-2026: 0.1%▼ -0.1 percentage points vs 03-2026 05-2026: 0.1%● unchanged vs 04-2026 06-2026: 0.2%▲ +0.1 percentage points vs 05-2026 07-2026: 0.1%▼ -0.1 percentage points vs 06-2026 08-2026: 0.1%● unchanged vs 07-2026 09-2026: 0.1%● unchanged vs 08-2026 10-2026: 0.1%● unchanged vs 09-2026lowest value 11-2026: 0.1%● unchanged vs 10-2026lowest value
Credit of up to €1,500 on 30-day terms is acceptable
Liquidity is tight, with a current ratio of 1.01 (1.01 in 2024), below the usual 1.5. Short-term debt is 94.9% and cash 84.6% of total assets. 95% of the assets are financed with debt and provisions.
Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (no NACE code, micro). It does better than 19% of them on solvency, 35% on liquidity, 90% on profitability and 47% on growth.

The bankruptcy probability was computed on 04-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

The probability rests on the annual accounts with balance sheet date 31-12-2025.

Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Five signals.
lowers riskraises riskneutral
lowers risk · Size: total assets €375,083
Companies of this size fail less often. How much that weighs depends on the rest of the company's profile.
NBB · annual accounts
lowers risk · No main activity registered
KBO
lowers risk · Liquidity: current ratio 1.01, cash €317,164
NBB · annual accounts
raises risk · Equity €18,600 (5.0% of total assets)
NBB · annual accounts
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 01-06-2026, 60 days ahead of the deadline.
NBB · 7 filings
Deviation from the deadline
2025
60 days early
2024
22 days early
2023
29 days late
2022
24 days late
2021
25 days late
2020
18 days early
2019
12 days late
← before the deadline after the deadline →
tick = median of all Belgian filings

The company filed its last 7 accounts on average 1 day before the deadline. The Belgian median for financial year 2024 was 4 days before the deadline, and 38% of all filings were late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 24 August (4 of the last 5 accounts filed within 46 days either side of that date).
Companies Code · seven months
Where today falls in the filing period
05-11-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
That holds for every publication since 2021.
KBO publications

Financials

Financials · financial year 2025, micro format

Annual accounts 2025 filed on 01-06-2026 PDF all 7 filings

Turnover
≈ €620,000
Estimated: probably between €420,000 and €960,000
Total assets
€375,083▼ 3.4%
2024 · €388,118
Net result
€183,501▲ 46.2%
2024 · €125,513
Working capital
€2,105▼ 35.2%
2024 · €3,249
Multi-year overview
2019 to 2025, 7 financial years
Operating result
€243,677
▲ 46.7% 2025
20192025
Net result
€183,501
▲ 46.2% 2025
20192025
Equity
€18,600
= 2025
20192025
Total assets
€375,083
▼ 3.4% 2025
20192025
Debt
€356,483
▼ 3.5% 2025
20192025
Working capital
€2,105
▼ 35.2% 2025
20192025
Every figure per financial year
Every figure with its change against the financial year before
favourable unfavourable
Line2019202020212022202320242025
Operating result€121,965-€106,500▼ 12.7%€102,261▼ 4.0%€137,945▲ 34.9%€168,027▲ 21.8%€166,133▼ 1.1%€243,677▲ 46.7%
Net result€94,290-€84,162▼ 10.7%€81,003▼ 3.8%€102,270▲ 26.3%€131,775▲ 28.9%€125,513▼ 4.8%€183,501▲ 46.2%
Equity€106,690-€190,852▲ 78.9%€271,855▲ 42.4%€380,324▲ 39.9%€18,600▼ 95.1%€18,600=€18,600=
Total assets€141,360-€227,255▲ 60.8%€283,438▲ 24.7%€388,097▲ 36.9%€377,215▼ 2.8%€388,118▲ 2.9%€375,083▼ 3.4%
Debt€34,670-€36,404▲ 5.0%€11,584▼ 68.2%€7,773▼ 32.9%€358,615▲ 46×€369,518▲ 3.0%€356,483▼ 3.5%
Working capital€102,668-€186,930▲ 82.1%€262,873▲ 40.6%€365,284▲ 39.0%-€368€3,249€2,105▼ 35.2%

The operating result for 2025 is 47% higher than in 2024 and the highest since 2019. It is a recovery after the fall in 2024.

Turnover and EBIT margin are not published. The micro format does not require them. The turnover shown is an estimate from the gross margin.

Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €375,083
Fixed assets €16,851 ▲ 7.9%
Current assets €358,232 ▼ 3.8%
Equity and liabilities €375,083
Equity €18,600 =
Debt €356,483 ▼ 3.5%
Debt's share of the balance-sheet total falls from 95.2% to 95.0%. Debt is lower.
Key figures and ratios
2025 value · change against 2024
EBITDA
€247,921▲
2024 · €169,480
Cash flow
€187,745▲
2024 · €128,860
Current ratio
1.01▼
2024 · 1.01
Debt to equity
19.17▼
2024 · 19.87
ROE
986.6%▲
2024 · 674.8%
ROA
48.9%▲
2024 · 32.3%
Interest coverage
over 100
2024 · over 100
Debt ≤ 1 year
€356,126▼
2024 · €369,249
Income taxes
€62,005▲
2024 · €42,483
Green means a favourable move, even when the figure itself falls, as with debt or debt to equity.

Investments

fixed assets acquired
Item20212022202320242025
Tangible fixed assets€8,000€3,388€6,500-€5,475
Financial fixed assets-€5,040---
Depreciation and write-downs of the year€2,940€2,369€2,573€3,347€4,245

Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)

Annual accounts
Filed annual accounts As filed with the NBB · 2025 against 2024 · 36 lines
Balance sheet Code20242025
Assets
Total assets20/58€388,118€375,083▼
Fixed assets21/28€15,621€16,851▲
Tangible fixed assets22/27€7,481€8,711▲
Land and buildings22€1,149€849▼
Plant, machinery and equipment23€54€2,791▲
Furniture and vehicles24€6,278€5,071▼
Financial fixed assets28€8,140€8,140=
Current assets29/58€372,497€358,232▼
Cash at bank and in hand54/58€352,079€317,164▼
Deferred charges and accrued income490/1€20,419€41,068▲
Equity and liabilities
Total equity and liabilities10/49€388,118€375,083▼
Equity10/15€18,600€18,600=
Contributions10/11€18,600€18,600=
Amounts payable17/49€369,518€356,483▼
Amounts payable within one year42/48€369,249€356,126▼
Trade debts44€926€891▼
Suppliers440/4€926€891▼
Taxes, remuneration and social security45€6,555€2,143▼
Taxes450/3€6,555€2,143▼
Other amounts payable47/48€361,768€353,092▼
Accrued charges and deferred income492/3€270€357▲
Income statement Code20242025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€3,347€4,245▲
Other operating charges640/8€882€816▼
Gross operating margin9900€170,362€248,738▲
Operating profit (loss)9901€166,133€243,677▲
Financial income75/76B€3,095€2,875▼
Recurring financial income75€3,095€2,875▼
Financial charges65/66B€1,232€1,046▼
Recurring financial charges65€1,232€1,046▼
Profit (loss) for the period before taxes9903€167,996€245,506▲
Income taxes67/77€42,483€62,005▲
Profit (loss) for the period9904€125,513€183,501▲
Profit (loss) for the period to be appropriated9905€125,513€183,501▲
Appropriation of the result
Profit (loss) to be appropriated9906€125,513€183,501▲
Profit to be distributed694/7€125,513€183,501▲
Return on contributions (dividend)694€125,513€183,501▲

The notes to these accounts have 6 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the filed accounts (PDF).

Source: Annual accounts 2025 (PDF), filed on 01-06-2026.

Line2019202020212022202320242025Change
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€1,121€554€2,940€2,369€2,573€3,347€4,245▲ 26.8%
Other operating charges640/8--€1,059€1,030€783€882€816▼ 7.5%
Gross operating margin9900€125,159€108,111€106,260€141,344€171,383€170,362€248,738▲ 46.0%
Operating profit (loss)9901€121,965€106,500€102,261€137,945€168,027€166,133€243,677▲ 46.7%
Financial income75/76B--€3€3€0€3,095€2,875▼ 7.1%
Recurring financial income75€16-€3€3€0€3,095€2,875▼ 7.1%
Financial charges65/66B--€208€986€646€1,232€1,046▼ 15.1%
Recurring financial charges65€49€276€208€986€646€1,232€1,046▼ 15.1%
Profit (loss) for the period before taxes9903€121,932€106,225€102,056€136,961€167,381€167,996€245,506▲ 46.1%
Income taxes67/77€27,642€22,063€21,053€34,691€35,606€42,483€62,005▲ 46.0%
Profit (loss) for the period9904€94,290€84,162€81,003€102,270€131,775€125,513€183,501▲ 46.2%
Profit (loss) for the period to be appropriated9905€94,290€84,162€81,003€102,270€131,775€125,513€183,501▲ 46.2%
Line2019202020212022202320242025Change
Assets
Total assets20/58€141,360€227,255€283,438€388,097€377,215€388,118€375,083▼ 3.4%
Fixed assets21/28€4,022€3,922€8,981€15,040€18,968€15,621€16,851▲ 7.9%
Tangible fixed assets22/27€922€822€5,881€6,900€10,828€7,481€8,711▲ 16.4%
Land and buildings22----€1,449€1,149€849▼ 26.1%
Plant, machinery and equipment23--€279€204€129€54€2,791▲ 52×
Furniture and vehicles24--€5,602€6,696€9,249€6,278€5,071▼ 19.2%
Financial fixed assets28€3,100€3,100€3,100€8,140€8,140€8,140€8,140=
Current assets29/58€137,338€223,334€274,457€373,056€358,247€372,497€358,232▼ 3.8%
Amounts receivable within one year40/41-€634€5,947€36,223€36,824---
Other amounts receivable41--€5,947€36,223€36,824---
Cash at bank and in hand54/58€136,402€221,799€267,590€318,541€318,408€352,079€317,164▼ 9.9%
Deferred charges and accrued income490/1--€920€18,293€3,015€20,419€41,068▲ 101%
Equity and liabilities
Total equity and liabilities10/49€141,360€227,255€283,438€388,097€377,215€388,118€375,083▼ 3.4%
Equity10/15€106,690€190,852€271,855€380,324€18,600€18,600€18,600=
Contributions10/11€12,400-€12,400€18,600€18,600€18,600€18,600=
Reserves13€94,290€178,452€178,452€361,724----
Distributable reserves133--€178,452€361,724----
Profit (loss) carried forward14--€81,003-----
Amounts payable17/49€34,670€36,404€11,584€7,773€358,615€369,518€356,483▼ 3.5%
Amounts payable within one year42/48€34,670€36,404€11,584€7,773€358,615€369,249€356,126▼ 3.6%
Trade debts44€2€931€171€81€722€926€891▼ 3.7%
Suppliers440/4--€171€81€722€926€891▼ 3.7%
Taxes, remuneration and social security45--€1,500€7,691€78,419€6,555€2,143▼ 67.3%
Taxes450/3--€1,500€7,691€77,419€6,555€2,143▼ 67.3%
Remuneration and social security454/9----€1,000---
Other amounts payable47/48--€9,913-€279,474€361,768€353,092▼ 2.4%
Accrued charges and deferred income492/3-----€270€357▲ 32.2%
Line2019202020212022202320242025Change
Profit (loss) for the period9904€94,290€84,162€81,003€102,270€131,775€125,513€183,501▲ 46.2%
+ Depreciation and write-downs630€1,121€554€2,940€2,369€2,573€3,347€4,245▲ 26.8%
Operating cash flow (approximation)€95,411€84,716€83,943€104,639€134,348€128,860€187,745▲ 45.7%
Investment in fixed assets (approximation)--€454-€8,000-€8,428-€6,500€0-€5,475-
Change in cash-€85,396€45,792€50,951-€133€33,670-€34,915-

A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.

Download as CSV

Historical observation

In July 2024, 2,153 companies had the same profile as Dr. Moons Anke has now. Two years later, 96.1% were still going and 1.7% had gone bankrupt.

  • Micro
  • 5 to 10 years old
  • solvency under 10%
  • a profit of 5% of the balance sheet or more
96.1% was still going
2.2% stopped otherwise
1.7% went bankrupt

The bankruptcy probability of Dr. Moons Anke itself is lower: 0.1% within 12 months. It rests on far more data about Dr. Moons Anke than the profile alone.

Test of the method

The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 3.0% 3.1%
10 5.6% 6.2%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 2,153 companies, not a prediction for Dr. Moons Anke. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Filings with the National Bank (7)
Financial year Type Filed Reference Document
31-12-2025 micro format 01-06-2026 2026-00128772 PDF
31-12-2024 micro format 09-07-2025 2025-00247270 PDF
31-12-2023 micro format 29-08-2024 2024-00390914 PDF
31-12-2022 micro format 24-08-2023 2023-00347274 PDF
31-12-2021 micro format 25-08-2022 2022-20315045 PDF
31-12-2020 micro format 13-07-2021 2021-35100007 PDF
31-12-2019 micro format 12-08-2020 2020-40800501 PDF

Board & ownership

Directors

Directors
1 director, last change in 2023
MOONS Anke
Director (not named in the articles) · appointed by deed of 20-09-2023 · earlier manager, until 20-09-2023 · term without a fixed end · listed in the 2025 annual accounts, filed on 01-06-2026
Current

Owners and capital

Capital transactions

Capital over time
  1. 20-09-2023 Converted to unavailable equity · €18,600

Mandate history

1 person, 1 in office
Show
  • Board
  • mandate already running before its first mention
Mandates per person, with start and end dates
Name Functions and periods
MOONS Anke
  • Manager, until 20-09-2023
  • Director (not named in the articles), appointed by deed of 20-09-2023, still in office
See the board, name and registered office on a given date →

Articles of association

Board ruleThese rules set how the board is made up, meets and takes decisions.
At least 1 director

Articles of association, deed of 20-09-2023 (in Dutch)

Network & group

Dr. Moons Anke shares no director with another company.

Connections & network

1 current director
Depth

The network starts from the directors of Dr. Moons Anke. Every other company they run is a node.

This company Company Director Shareholding +N: links not shown yet Click a node to look further, drag to arrange, zoom with the mouse wheel.

Timeline

Deeds, filings and financial milestones

Deadline for the 2026 accounts: 31-07-2027
2026
01-06
NBB filing Annual accounts 2025 filedPDF
micro format · 60 days before the deadline
2025
31-12
Financial Highest result from 2019 to 2025net €183,501 ▲46.2%
The operating result of €243,677 and the net result of €183,501 are both a record.
09-07
NBB filing Annual accounts 2024 filedPDF
micro format · 22 days before the deadline
2024
29-08
NBB filing Annual accounts 2023 filedPDF
micro format · 29 days late
2023
20-09
Gazette deed Change of role: MOONS Anke, from manager to director
“De uitoefening van de geneeskunde door de arts-aandeelhouders,zijnde meer in het bijzonder huisarts,in naam en…” (deed in Dutch)6 points ▸
  • General meeting, 06-09-2023
  • 100 shares
  • Director resignation, MOONS Anke (manager)
  • Director appointment, MOONS Anke (director (not named in the articles))
  • Registered office clause, Kruisvijverstraat 14
  • Power of attorney, Yves DE CEUNYNCK
  • The deed holds 4 more points.

Open the deed in the Belgian Official Gazette

24-08
NBB filing Annual accounts 2022 filedPDF
micro format · 24 days late
2022
31-12
Financial Liquidity doublescurrent ratio 48.00
The current ratio rises from 23.69 to 48.00. Short-term debt falls from €11,584 to €7,773.
25-08
NBB filing Annual accounts 2021 filedPDF
micro format · 25 days late
2021
31-12
Financial Liquidity more than triplescurrent ratio 23.69
The current ratio rises from 6.13 to 23.69. Short-term debt falls from €36,404 to €11,584.
31-12
Financial Equity above €200,000equity €271,855 ▲42.4%
With a profit in every financial year since 2019, equity grows to €271,855.
13-07
NBB filing Annual accounts 2020 filedPDF
micro format · 18 days before the deadline
2020
31-12
Financial Equity above €150,000equity €190,852 ▲78.9%
With a profit in every financial year since 2019, equity grows to €190,852.
12-08
NBB filing Annual accounts 2019 filedPDF
micro format · 12 days late
2018
30-08
Gazette deed IncorporationPDF
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.

Sources:Publications in the Belgian Official GazetteFilings with the National Bank

History

Dr. Moons Anke was incorporated on 28 August 2018.1 Total assets rose from €141,360 in 2019 to €375,083 in 2025.2

  1. 1KBO register
  2. 2National Bank, annual accounts 2019 and 2025

Company details

Register details

Identity

KBO record
Name Dr. Moons Anke in Dutch
Enterprise number 0701.835.283
Legal form Private limited company
Status Active, normal situation
Founded 28-08-2018
Entity type Legal entity
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
deed of 20-09-2023 (in Dutch)
Name clauseThe company operates under this name according to its articles.
Dr.Moons Anke
deed of 20-09-2023 (in Dutch)
Registered office clauseThe articles name the region of the registered office. The language of official documents depends on that region, among other things.
“Vlaams Gewest”
deed of 20-09-2023 (in Dutch)

Registered office and establishments

Registered office Kruisvijverstraat 14, 3550 Heusden-Zolder, Belgium
Establishment unit Mouterijstraat 16, 3582 Beringen since 28-08-2018 · unit number 2.279.241.860 86210 General medical practice

Activities

PurposeThe purpose describes the activities the company may carry out under its articles.
“De uitoefening van de geneeskunde door de arts-aandeelhouders,zijnde meer in het bijzonder huisarts,in naam en voor rekening van de…”
14 activities
  1. De uitoefening van de geneeskunde door de arts-aandeelhouders,zijnde meer in het bijzonder huisarts,in naam en voor rekening van de vennootschap,met inachtname van de regels van de medische deontologie.
  2. De geneeskunde wordt uitgeoefend onder de specifieke beroepsaansprakelijkheid van de aandeelhouders en de bijkomende aansprakelijkheid van de vennootschap.
  3. De activiteit omvat impliciet de inning van de erelonen door en voor de vennootschap en de betaling aan de arts-aandeelhouder van een vergoeding in verhouding tot de prestatie die hij voor rekening van de vennootschap geleverd heeft.
  4. Het ter beschikking stellen van alle nodige middelen aan de arts/artsen die tot de vennootschap zijn toegetreden;het inrichten van algemene diensten en een medisch secretariaat in het bijzonder,die nuttig of nodig zijn voor de uitoefening van voornoemde activiteiten.
  5. De aankoop,het huren en/of leasen van alle medische apparatuur en begeleidende accommodaties,inclusief gebouwen,kortom van een volledige materiële infrastructuur om deze ter beschikking te stellen van de arts-aandeelhouder voor de voornoemde activiteiten.
  6. Mits inachtname van de Code Medische Deontologie,mag de vennootschap alle onroerende en roerende verrichtingen uitvoeren die van aard zijn rechtstreeks of onrechtstreeks de verwezenlijking van haar voorwerp te bevorderen,te vergemakkelijken of te begunstigen.
  7. Het aanleggen van reserves teneinde alle nodige apparaten en gebouwen aan te schaffen,nodig of nuttig om voornoemd voorwerp te bereiken,evenals het beheer van deze reserves als een goed huisvader.
  8. De mogelijkheid scheppen om de arts-aandeelhouder of arts-aandeelhouders toe te laten zich verder te bekwamen ten einde in hun discipline aan de spits van de evolutie te blijven.
  9. De artsen-aandeelhouders die allen ingeschreven dienen te zijn op de Lijst van de Orde der Artsen en die hun beroep op actieve wijze dienen uit te oefenen,verbinden er zich toe hun volledige medische activiteit in de vennootschap te brengen en alle daaruit voortvloeiende honoraria zullen geïnd worden door en voor de vennootschap.
  10. De vennootschap mag overeenkomsten afsluiten met en samenwerken met alle verenigingen,rechtspersonen en vennootschappen die een gelijkaardig voorwerp nastreven of die bijdragen tot de algehele of gedeeltelijke verwezenlijking van het voorwerp.
  11. De aandeelhouders zullen steeds de Medische Deontologie van de Orde der Artsen naleven.
  12. Overeenkomsten die artsen omwille van deontologische redenen niet mogen afsluiten mogen evenmin door de vennootschap worden afgesloten.
  13. De vennootschap kan enkel toetreden tot een(kosten)associatie,een middelenvennootschap of een vzw.
  14. De vennootschap kan als bijkomstig voorwerp alle roerende en onroerende goederen en rechten verwerven en beheren en rechtshandelingen dienaangaande stellen,zonder dat deze activiteit een regelmatig en commercieel karakter mag krijgen,en indien tussen de aandeelhouders een voorafgaandelijk akkoord over de investeringsmodaliteiten met ten minste een 2/3de meerderheid schriftelijk wordt vastgelegd.
deed of 20-09-2023 (in Dutch)

Invoicing and payment

VAT number BE 0701.835.283
E-invoicing via Peppol
Reachable via Peppol
Peppol ID 0208:0701835283

Follow this company and you will hear the next morning if it leaves the Peppol register.

Register as of 4 November 2026 · Peppol Directory

Financial year and general meeting

Accounts at the NBB
Financial year end 31-12
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
Second Thursday of June at 20:00
deed of 20-09-2023 (in Dutch)

Sites & property

Location
registered office establishment The establishment unit on the map

Buildings and parcels at the addresses

Ground area
4,019 m²
Building footprint
410 m²
Building volume
2,114 m³
Tallest building: 15.4 m.
Cadastral parcel Region Area Buildings Height / floors
71029B0490/00D000 Flanders 3,056 m² 1 · 286 m² 7.1 m · 2
71025A1561/00M003 Flanders 963 m² 1 · 123 m² 15.4 m · 2